Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
Public ClinicalTrials.gov record NCT03245385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Safety Study to Assess the Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray (Sun Pharmaceuticals Industries Limited) in Patients With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe atopic dermatitis. At least 40 eligible patients with atopic dermatitis that satisfy all eligibility criteria will be enrolled into the study
Study identification
- NCT ID
- NCT03245385
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2017
- Primary completion
- Feb 4, 2018
- Completion
- Feb 4, 2018
- Last update posted
- Sep 24, 2019
2017 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Clinical Research | North Hollywood | California | 91606 | — |
| Havana Research Institute | Pasadena | California | 91105 | — |
| Vital Pharma Research | Hialeah | Florida | 33016 | — |
| Solutions Through Advanced Research | Jacksonville | Florida | 32256 | — |
| Integrity Research Center | Miami | Florida | 33015 | — |
| Millennium Clinical Research, INC | Miami | Florida | 33125 | — |
| Regenerate Clinical Trials, LLC | Miami | Florida | 33155 | — |
| Life Medical Center and Research, INC | Miami | Florida | 33166 | — |
| Vista Health Research | Miami | Florida | 33176 | — |
| Elias Research | Troy | Michigan | 48085 | — |
| Montana Medical Research/Elias Research Assoc. | Missoula | Montana | 49808 | — |
| L&C Professional Medical Research Institute | Hazleton | Pennsylvania | 18201 | — |
| Sun Research Institute | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03245385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2019 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03245385 live on ClinicalTrials.gov.